News | October 06, 2025
Lilly to invest $1 billion+ in new contract manufacturing in India
Investment to expand manufacturing and global medicine supply capacity
Investment to expand manufacturing and global medicine supply capacity
Hyperion results presented at ERS 2025 and simultaneously published in the New England Journal of Medicine
The new site enables end-to-end production of viral vector gene therapies
The positive opinion is based on results from KOMET, the largest and only placebo-controlled, double-blind global Phase III trial in this patient population
The new Houston site, Lilly's eighth U.S. manufacturing facility announced since 2020, will focus on domestic production of small molecule synthetic medicines
Tezspire nearly eliminated the need for surgery, reducing surgical intervention by 98 per cent
The TULIP-SC trial investigated the efficacy and safety of subcutaneous Saphnelo
Bayer Co.Lab AdVenture platform will accelerate biotech innovation through global investment networks
Pete Pharma will leverage FABRX’s extensive foundation of scientific validation to deliver a commercially viable, pharmacy-ready solution in the US
ProBioGen will oversee the design, construction, and operation of the 4,600-square-meter GMP manufacturing unit
Subscribe To Our Newsletter & Stay Updated
